244 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eli Lilly
Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pharmaceutical
Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Azaphilones from an Acid Mine Extremophile Strain of a Pleurostomophora sp.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Memorial Sloan-Kettering Cancer Center
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Minnesota
N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Navarra
1,3,4-Thiadiazoles: a potent multi targeted pharmacological scaffold.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Mississippi
2-Benzisothiazolylimino-5-benzylidene-4-thiazolidinones as protective agents against cartilage destruction.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Catania
Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eli Lilly
Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universidad Ceu San Pablo
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Asahi Kasei Pharma
Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Second Military Medical University
Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pomona College
Three-dimensional quantitative structure-activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin-1 (MMP-3) inhibitors: applying a"divide and conquer" strategy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Missouri St. Louis
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
East China University of Science and Technology
Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Alantos Pharmaceuticals
Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Panthera Biopharma
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Florida
Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Incyte
1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Johnson & Johnson Pharmaceutical Research and Development
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Johnson & Johnson Pharmaceutical Research & Development
Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Johnson & Johnson Pharmaceutical Research and Development
Noreupenifeldin, a tropolone from an unidentified ascomycete.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
The Hebrew University of Jerusalem
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Research and Development
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
The Hebrew University of Jerusalem
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Institut De Recherches Servier
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nippon Organon K.K.
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dupont Pharmaceuticals
Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Parke-Davis Pharmaceutical Research
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Procter and Gamble Pharmaceuticals
Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Procter and Gamble Pharmaceuticals
Discovery of potent, achiral matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Procter and Gamble Pharmaceuticals
Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Heterocycle-based MMP inhibitors with P2' substituents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Procter and Gamble Pharmaceuticals
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Celltech-Chiroscience
Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dupont Pharmaceuticals
Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Cambridge
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl)
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Boehringer Ingelheim Pharmaceuticals
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Instituto Superior T£Cnico
Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Johnson & Johnson Pharmaceutical Research & Development
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Illinois At Chicago
Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Structure and activity relationships of tartrate-based TACE inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Central Pharmaceutical Research Institute
Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Yonsei University
Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Schering-Plough Research Institute
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Gsk Medicines Research Centre
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Schering-Plough Research Institute
Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moiety![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Potent carboxylate inhibitors of stromelysin containing P2′ piperazic acids and P1′ biaryl moeities![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Potent matrix metalloproteinase inhibitors: Amino-carboxylate compounds containing modifications of the P1 residue![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2′-P3′ amide bond isostere![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1'![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Hydroxamate inhibitors of the matrix metallo-proteinases (MMPs) containing novel P1′ heteroatom based modifications![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalanines![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Potent and selective inhibitors of gelatinase-A 2. carboxylic and phosphonic acid derivatives![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Incyte
Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of California
Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Athens
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Université
The berkeleyamides, amides from the acid lake fungus Penicillum rubrum.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Montana Tech of The University of Montana
Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Università
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Johnson & Johnson Pharmaceutical Research and Development
Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Incyte
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Incyte
Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Università
Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Université
Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Clermont Auvergne University
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Incyte
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Università
Identification of potent and selective TACE inhibitors via the S1 pocket.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Johnson & Johnson Pharmaceutical Research and Development
A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Institutes For Biomedical Research
Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Aventis Pharma Deutschland
N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Università
Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
QSAR-by-NMR: quantitative insights into structural determinants for binding affinity by analysis of 1H/15N chemical shift differences in MMP-3 ligands.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Aventis Pharma Deutschland
Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pharmaceutical Research Institute
3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of California San Francisco
Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hokkaido Collaboration Center N-21
Synthesis and biological activity of selective azasugar-based TACE inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Organon K.K.
MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Umr/Cnrs 6013
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hokkaido Collaboration Center
Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hokkaido Collaboration Center
Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Indiana University School of Medicine
Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Organon K.K.
NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb
Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Organon K.K.
New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Organon K.K.
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dupont Pharmaceuticals
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
British Biotech Pharmaceuticals
Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Université
N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Université
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Procter and Gamble Pharmaceuticals
A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
The Royal Danish School of Pharmacy
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Roche Research Center
Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Procter and Gamble Pharmaceuticals
Chemoenzymatic synthesis of functionalized cyclohexylglycines and alpha-methylcyclohexylglycines via Kazmaier-Claisen rearrangement.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Florida
Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Institut De Recherches Servier
Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Procter and Gamble Pharmaceuticals
Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Roche Pharma Research and Early Development
Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eli Lilly
Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Procter and Gamble Pharmaceuticals
Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Florida
Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hoechst Marion Roussel
Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Smithkline Beecham Pharmaceuticals
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
British Biotech Pharmaceuticals
P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dupont Pharmaceuticals
Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Searle Discovery Research
Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pharmacia and Upjohn
Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
RhôNe-Poulenc Rorer
Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Design and synthesis of conformationally-constrained MMP inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Procter and Gamble Pharmaceuticals
Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth-Ayerst Research
Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Affymax Research Institute
Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dupont Pharmaceuticals
Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Affymax Research Institute
Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dupont Pharmaceuticals
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kanebo
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shionogi
Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Institut De Recherche Servier
Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Warner-Lambert
Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxo Inc. Research Institute
Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sterling Winthrop Pharmaceuticals Research Division
Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Preclinical Research Novartis Pharma
The Berkeleylactones, Antibiotic Macrolides from Fungal Coculture.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Illinois At Chicago
Lung cancer and matrix metalloproteinases inhibitors of polyphenols from Selaginella tamariscina with suppression activity of migration.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Guangxi Normal University
Discovery of dehydroabietic acid sulfonamide based derivatives as selective matrix metalloproteinases inactivators that inhibit cell migration and proliferation.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Southeast University
Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nestl�
Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Graz University of Technology
Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universidad De Navarra
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
St. John'S University
Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Scripps Florida
Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Universit?? Di Firenze
Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Suven Life Sciences
Tyrosinase inhibition: conformational analysis based studies on molecular dynamics calculations of bipiperidine based inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
University of Karachi
DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Suntory Institute For Bioorganic Research
Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Georgetown University
Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Syntex Discovery Research
Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Vernalis (R&D)